Systemic and brain bioavailabilities of d-Phenylglycine-l-Dopa, a sustained dopamine-releasing prodrug

d-Phenylglycine-l-Dopa (d-PhG-l-Dopa), designed as a dipeptide mimetic prodrug of dopamine, has been proven to have 31-fold higher oral bioavailability than l-Dopa in rats. To further investigate if this dipeptide enters the brain, a single-dose pharmacokinetic study by i.v. administration, in comparison with l-Dopa, was conducted to monitor brain availability. The dopamine level in the brain was also determined. The results indicated that both d-PhG-l-Dopa and l-Dopa entered the brain rapidly (Tmax 1 minute) with similar degrees of penetration (AUCbrain/AUCplasma 8.83% vs. 7.61%). As d-PhG-l-Dopa had higher systemic exposure than l-Dopa (AUCplasma 23.79 μmol*min/mL vs. 12.09 μmol*min/mL), it thus had higher brain availability (AUCbrain 2.0 μmol*min/mL vs. 0.92 μmol*min/mL). Although the AUCbrain dopamine after d-PhG-l-Dopa treatment was only 24% of that from l-Dopa treatment, it however exhibited higher anti-Parkinsonism activity than l-Dopa (reduction in rotation number 47.9 ± 5.5% vs. 27.3 ± 4.8%). Higher brain dopamine residual properties of d-PhG-l-Dopa treatment compared to l-Dopa treatment, namely 3.2 times longer MRTbrain dopamine (172.15 vs. 53.78 minutes), 10 times longer Tmax brain dopamine (30 vs. 3 minutes) and 8.36 times longer half-life (T1/2Tmaxtoend(min) 112.51 vs. 13.46 minutes), may explain the result. Moreover, the long terminal half-life of brain dopamine upon d-PhG-l-Dopa treatment indicated its slow dopamine-releasing property compared with l-Dopa treatment (112.51 vs. 44.85 minutes). It is also important to note that brain dopamine level was better controlled in the d-PhG-l-Dopa group than in the l-Dopa group (Cmax/Cmin 1.62 vs. 9.85). In conclusion, this study demonstrated that d-PhG-l-Dopa is an intrinsic dopamine-sustained-releasing prodrug. The limited concentration fluctuation of released dopamine in the brain is beneficial for the clinical management of Parkinson's disease.